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Disseminated bone lesions in AIDS-associated Kaposi sarcoma, a
bad prognosis? About four cases
Wassilew, N; Ciaffi, L; Vu, D; Calmy, A and Toutous Trellu, L
University Hospital Geneva, Infectious Diseases, Geneva, Switzerland.
Kaposi sarcoma (KS) can present with a wide range of clinical features ranging from minimal cutaneous disease to a rapidly
progressing neoplasm. Bone lesions are most often discovered accidently in the context of radiological investigations done for
the screening of KS-visceral involvement [1]. Little is known on clinical outcome and response to antiretroviral therapy (ART)
and/or chemotherapy of these lytic osseous lesions. We report four cases with bone involvement in the context of systemic KS
and aim at describing the long-term clinical outcome in two of these patients. Cases of AIDS-associated KS with disseminated
bone lesions were collected in the HIV Unit, University Hospital Geneva, Switzerland. Patients were compared on clinical,
biological and radiological features and therapeutic responses. Between 2002 and 2012, four HIV1-infected patients with T1
stage of KS presented disseminated osseous lesions (Table 1). Mean age was 43 years (range 39 - 47 years), mean time of follow
up until our analysis was 48.5 months (SD 53.8), and mean CD4 count at KS diagnosis was 190.5 c/mL (SD 202.8). All patients
showed hypodense bone lesions predominating the axial skeleton (figure 1), but no radiological imaging was performed to
search for peripheral bone lesions.
No patient reported pain or experienced pathological fractures. In one patient a dual-energy X-ray absorptiometry (DXA) showed
a bone mineral density within normal range after 10 years of KS diagnosis with disseminated bone lesions. No radiological
change was observed in that patient despite stable KS disease after 13 cycles of liposomal doxorubicin and ART (figure 1). We
describe a well-documented long-term follow up of disseminated osseous AIDS-associated KS disease. In our four cases, lytic
bone lesions were asymptomatic and were not associated with bone fragility.We even could confirm the KS nature of the lesions
by bone biopsy in patient B (3 months after KS diagnosis), as the differential diagnosis is wide, and include bacillary
angiomatosis, cancers or metastasis. Chemotherapy and antiretroviral treatment did not affect bone lesions using CT scan
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Figure 1. Patient with 10yr follow up, lumbar vertebre after 6 (2002) and 13 (2012) sycles of chemotherapy with Liposomal Doxorubicin.
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1despite a good response on other KS-affected sites. Prognostic factors are well established in AIDS-associated KS [2]; however
disseminated bone disease does not seem to have an impact on disease evolution. A larger sample size is needed to confirm this
hypothesis.
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2Table 1. Baseline characteristics for all four patients with AIDS-related KS and osseous lesions. Staging classification is based on Known SE et al. J Clin Oncol 1989; 7: 12017 and includes
the following parameters: T for Tumor (T0 KS confined to skin and minimal oral disease, T1 all other manifestations), I for Immune system (I0 CD4 cells  200/ mL and I1 CD4
cells B200 mL) and S for systemic illness (S0 no history of opportunistic infections, S1 history of opportunistic infections and thrush)
Patient Sex Age Ethnicity
Kaposi
stage
(TIS)
Follow-up
time since KS
diagnosis
Visceral
involvement
Bone lesion
(imaging)
HHV8 viremia at
KS diagnosis (full
blood c/mL)
Chemotherapy (first line,
number of cycles, time period)
Last HIV-
RNA (c/
mL)
ART
including PI
(y/n) Special comment
A M 47 (1965) CAU 1/1/1 10 years yes Axial skeleton,
disseminated,
hypodense (CT scan)
n.a. Liposomal Doxorubicin
(13, 19992004)
B 20 yes DXA-scan BMD
within normal
range
B M 45 (1969) SSA 1/1/1 8 months Yes Axial skeleton,
disseminated,
hypodense (CT scan)
2200 Paclitaxel
(4, 2012ongoing)
45 yes KS confirmation
by bone biopsy
C M 41 (1971) SSA 1/0/1 5 years Yes Axial skeleton,
disseminated,
hypodense (CT scan)
Not done none 94 no
D M 39 (1973) SSA 1/1/1 6 months Yes Axial skeleton, single
lesions, hypodense
(CT scan)
62200 Paclitaxel (3, 2012ongoing) B 20 yes (but
stop May
2012)
(Abbreviations: SSA Sub Saharan Africa; CAU Caucasian; n.a.not available DXA Dual-energy X-ray absorptiometry; BMD bone mineral density)
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